FDMT logo

FDMT
4D Molecular Therapeutics Inc

1,268
Mkt Cap
$544.7M
Volume
737,281.00
52W High
$12.34
52W Low
$3.00
PE Ratio
-4.14
FDMT Fundamentals
Price
$9.93
Prev Close
$10.42
Open
$10.39
50D MA
$9.36
Beta
1.33
Avg. Volume
693,290.37
EPS (Annual)
-$2.42
P/B
1.19
Rev/Employee
$434,739.80
$53.23
Loading...
Loading...
News
all
press releases
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of +7.24% and +46.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11h ago
News Placeholder
More News
News Placeholder
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are covering the stock, Marketbeat.com...
MarketBeat·17d ago
News Placeholder
electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?
electroCore (ECOR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·27d ago
News Placeholder
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. decreased its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 55.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 296,199 shares of the company's stock after...
MarketBeat·1mo ago
News Placeholder
4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at Jefferies Financial Group
Jefferies Financial Group reiterated a "buy" rating and issued a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday...
MarketBeat·1mo ago
News Placeholder
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has earned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat Ratings...
MarketBeat·1mo ago
News Placeholder
4D Molecular Therapeutics (NASDAQ:FDMT) Sees Unusually-High Trading Volume - Here's Why
4D Molecular Therapeutics (NASDAQ:FDMT) Sees Large Volume Increase - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's Why
4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Research Analysts Issue Forecasts for FDMT FY2030 Earnings
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Investment analysts at HC Wainwright issued their FY2030 earnings estimates for shares of 4D Molecular Therapeutics in a research note issued on Friday, March 20th. HC Wainwright analyst M. Caufield forecasts that the company will earn...
MarketBeat·2mo ago
News Placeholder
4D Molecular Therapeutics (NASDAQ:FDMT) Raised to "Hold" at Wall Street Zen
Wall Street Zen raised shares of 4D Molecular Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·2mo ago
<
1
2
...
>

Latest FDMT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.